The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer trial in Europe to add 11 new sites across Germany, Poland, and Spain.

Based on the interest of principal investigators at additional sites, the Company plans to submit applications to EMA regulators to add 5-10 additional sites in Ireland, Romania, and potentially other ...

Greenwich LifeSciences (GLSI), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is ...

STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical ...

Greenwich LifeSciences (GLSI) stock gained after the company updated on commercial manufacturing of its lead candidate GP2.

Check the time stamp on this data. Updated AI-Generated Signals for Greenwich Lifesciences Inc. (GLSI) available here: GLSI.

STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In the last year, multiple insiders have substantially increased their holdings of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) stock, indicating that insiders' optimism about the company's prospects ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...